Autifony Therapeutics Limited

Alzheimer's disease affects 1% of the world's population. Given the ageing population, 115 million people are expected to suffer from the disease by 2050. The impact on the lives of patients, their families and society in general is huge. In the UK, there are estimated to be over 670,000 people acting as primary, unpaid carers for people with dementia. De...

AUT00206 is a new drug that has been characterised in preclinical studies under an Early Stage Innovate UK award (Ref. 101443) due to complete in 2Q15. '206 acts on Kv3 channels that are implicated in brain circuits believed to be dysfunctional in schizophrenia. This pioneering proposal builds on the preclinical work to take ‘206 into the clinic, and cond...

Tinnitus is a chronic, under-recognised condition that affects over 10% of adults, causing significant suffering. There are no approved drugs and current treatments, such as counselling, only help patients to cope with symptoms. This project will provide clinical proof-of-concept evaluation of the efficacy of a novel ion channel drug in patients with tinn...

The Autifony-Newcastle-Manchester consortium will develop a new treatment for schizophrenia that targets a novel brain potassium channel, Kv3, that is intimately linked to the emerging understanding of the pathology of the disorder. This first-in-class treatment has the potential to address significant unmet patient need for schizophrenia, a serious psych...